1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. North America Cancer Immunotherapy Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Rising cancer incidence
3.2.1.2. Growing awareness and acceptance of immunotherapy
3.2.1.3. Increasing government initiatives
3.2.2. Restraints
3.2.2.1. High cost of treatment
3.2.2.2. Increasing safety concerns
3.2.2.3. Complex regulatory landscape
3.2.3. Opportunities
3.2.3.1. Development of new and improved immunotherapy drugs
3.2.3.2. Growing focus on personalized medicine
3.2.3.3. Expansion into new indications
3.2.4. Challenges
3.2.4.1. Educating patients and healthcare providers
3.2.4.2. Manufacturing challenges
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. North America Cancer Immunotherapy Market: Marketing Strategies
5. North America Cancer Immunotherapy Market Overview
5.1. Market Size & Forecast, 2019-2030
5.1.1. By Value (USD Billion)
5.2. Market Share and Forecast
5.2.1. By Type of Therapy
5.2.1.1. Checkpoint Inhibitors
5.2.1.2. Monoclonal Antibodies
5.2.1.3. Vaccines
5.2.1.4. Cell Therapies
5.2.1.5. Immunomodulators
5.2.1.6. Oncolytic Virus
5.2.2. By Distribution Channel
5.2.2.1. Hospital Pharmacy
5.2.2.2. Retail Pharmacy
5.2.2.3. Online Pharmacy
5.2.3. By Application
5.2.3.1. Lung Cancer
5.2.3.2. Breast Cancer
5.2.3.3. Colorectal Cancer
5.2.3.4. Melanoma
5.2.3.5. Prostate Cancer
5.2.3.6. Others (Ovarian Cancer, Pancreatic Cancer)
5.2.4. By End User
5.2.4.1. Hospitals & Clinics
5.2.4.2. Cancer Research Centers
5.2.4.3. Others
5.2.5. By Country
5.2.5.1. United States
5.2.5.2. Canada
6. United States Cancer Immunotherapy Market
6.1. Market Size & Forecast, 2019-2030
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Type of Therapy
6.2.2. By Distribution Channel
6.2.3. By Application
6.2.4. By End User
7. Canada Cancer Immunotherapy Market
7.1. Market Size & Forecast, 2019-2030
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Type of Therapy
7.2.2. By Distribution Channel
7.2.3. By Application
7.2.4. By End User
8. Competitive Landscape
8.1. List of Key Players and Their Offerings
8.2. North America Cancer Immunotherapy Market Share Analysis, 2023
8.3. Competitive Benchmarking, By Operating Parameters
8.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
9. North America Cancer Immunotherapy Market: Import & Export
10. Impact of Geopolitical Tensions on North America Cancer Immunotherapy Market
11. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
11.1. Pfizer Inc.
11.2. AstraZeneca
11.3. Merck & Co., Inc
11.4. F. Hoffmann-La Roche Ltd
11.5. Bristol-Myers Squibb Company
11.6. Novartis AG
11.7. Lilly
11.8. Johnson & Johnson Services, Inc
11.9. Bayer AG
11.10. Astellas Pharma Inc.
11.11. Gilead Sciences, Inc
11.12. GSK plc
11.13. Sanofi
11.14. AbbVie Inc.
11.15. Atara Biotherapeutics, Inc
11.16. Other Prominent Players
12. Key Strategic Recommendations
13. Research Methodology
13.1. Qualitative Research
13.1.1. Primary & Secondary Research
13.2. Quantitative Research
13.3. Market Breakdown & Data Triangulation
13.3.1. Secondary Research
13.3.2. Primary Research
13.4. Breakdown of Primary Research Respondents, By Region
13.5. Assumptions & Limitations
*Financial information of case of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable